Special Issue "Anti-Obesity Drugs"

Guest Editor
Prof. Dr. Raj Padwal
Clinical Pharmacology and General Internal Medicine, University of Alberta, 2F1.26 Walter C. Mackenzie Health Sciences Center, 844-0112 Street Edmonton, Alberta, T6G 2B7, USA
E-Mail:

Submission Information

All papers should be submitted to pharmaceuticals@mdpi.com. To be published continuously until the deadline and papers will be listed together at the special issue website.

Submitted papers should not have been published nor be under consideration for publication elsewhere. All papers are refereed through a peer-review process. A guide for authors is available on the Instructions for Authors page. Pharmaceuticals is a new international, peer-reviewed, quarterly open access journal published by MDPI.

Article Processing Charges (APC) for publication in this open access journal are waived for well-prepared manuscripts submitted by 30 June 2010. English correction or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those paper accepted for publication, that require extensive additional formatting and/or English corrections.

• antiobesity drug
• sibutramine
• orlistat
• lipase inhibitor
• cetilistat
• contrave
• empatic
• buproprion
• zonisamide
• naltrexone
• tesofensine
• endocannabinoid receptor blocker
• rimonabant
• incretin
• beta-3 blocker
• adrenergic reuptake inhibitor
• lorcaserin
• serotonin agonist

Manuscript ID: Pharmaceuticals-antiobsi-20090905-Tzotzas-gr
Type of Paper: Review
Title: The Effect of Incretin-Based Pharmacotherapy on Body Weight
Author: Spiridon Karras, Gerasimos Krassas and Themistoklis Tzotzas; E-Mail: tzotzas@otenet.gr
Abstract: Incretin–based pharmacotherapy, represented by Glucagon-Like Peptide-1(GLP-1) mimetics and DPP-4 inhibitors, offers a new therapeutic approach in Type 2 Diabetes Mellitus (T2DM).These glucosemodulatory agents enhance insulin secretion, lower fasting and postprandial glucose, suppress glucagon secretion and may have pleiotropic metabolic effects; additionally, they participate in the reduction of gastric emptying. Clinical studies demonstrated that GLP-1 mimetics increase postprandial satiety leading to reduced food intake and weight loss. These drugs induce food intake suppression mediated by distinct, but overlapping, peripheral and central pathways. On the contrary, DPP-4 inhibitors have a weight neutral effect. This review summarizes the current knowledge on the effect of incretin–based pharmacotherapy on body weight in T2DM and proposes an integrated model of the incretins on food intake .